ABIVAX company profile

ABVX · Euronext Paris · EUR

Compare ABIVAX
€63.00Change from previous close: −17.21%Absolute change: −€13.10

Close · November 20, 2026

Company profile

ABIVAX has 98 employees and is headquartered in Paris, France.

Obefazimod, the lead candidate in its pipeline, is the centre of ABIVAX's work and is being evaluated in moderately to severely active ulcerative colitis, with a separate study running in Crohn's disease. The Paris-based company, a clinical-stage biotech, develops therapies that draw on the body's own regulatory mechanisms to steady the immune response in people with chronic inflammatory diseases. Its programmes are aimed at patients suffering from chronic inflammatory conditions.

Revenue came to 4.6 million euros in the fiscal year ended 31 December 2025, down 63.2% on the prior year, while the net loss for that period reached 336.1 million euros. The company employs 98 people across its operations and has its headquarters in Paris, France, where it was incorporated in 2013.

Company facts

Industry
Biotechnology
Country
France
Headquarters
7-11 Boulevard Haussmann, 75009, Paris
Employees
98
Chief executive
Marc M. de Garidel
Founded
2013
Fiscal year
January - December
Listing
ABVX · Euronext Paris
Currency
EUR
ISIN
FR0012333284
Website
abivax.com

ABIVAX and its competitors

The most similar companies by business and size

CompanyCountryMarket capEmployeesOperating marginP/E (trailing 12 months)
ABIVAXABVXFrance$6.06B98-6,270.4%—
Bachem HoldingBANBSwitzerland$6.84B2,72521.8%38.7
ALK-AbellóALK.BDenmark$7.79B2,79526.6%38.0
CamurusCAMXSweden$4.32B32337.4%58.7
Financière de TubizeTUBBelgium$11.25B30.0%104.1
Bavarian NordicBAVADenmark$2.72B1,92318.1%12.7

Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.

Compare ABIVAX with its competitors